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with pneumonia treated with ceftobiprole:
a retrospective analysis of two major trials
Thomas W. L. Scheeren1, Tobias Welte2, Mikael Saulay3, Marc Engelhardt4, Anne Santerre-Henriksen4
and Kamal Hamed4*Abstract
Background: Patients with pneumonia who are elderly or severely ill are at a particularly high risk of mortality. This
post hoc retrospective analysis of data from two Phase III studies evaluated early improvement outcomes in
subgroups of high-risk patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia
(HAP, excluding ventilator-associated pneumonia [VAP]).
Methods: One study included hospitalised CAP patients randomised to ceftobiprole or ceftriaxone ± linezolid
treatment. The other study included HAP patients, who were randomised to ceftobiprole or ceftazidime plus linezolid
treatment. The primary outcome was rate of early clinical response (Day 3 in CAP and Day 4 in HAP patients).
Additional outcome measures included clinical cure at a test-of-cure visit, 30-day all-cause mortality and safety.
Results: The overall high-risk group comprised 398 CAP patients and 307 HAP patients with risk factors present at
baseline. The rate of early response was numerically higher in ceftobiprole-treated patients vs comparator-treated
patients in the following high-risk groups: CAP patients aged ≥75 years (16.3% difference, 95% confidence interval [CI]:
1.8, 30.8); CAP patients with COPD (20.1% difference, 95% CI: 8.8, 31.1); all high-risk HAP patients (12.5% difference, 95%
CI: 3.5, 21.4); HAP patients with >10 baseline comorbidities (15.3% difference, 95% CI: 0.3, 30.4).
Conclusions: Previous studies show that ceftobiprole is an efficacious therapy for patients with pneumonia who are at
high risk of poor outcomes. This post hoc analysis provides preliminary evidence that ceftobiprole treatment may have
advantages over other antibiotics in terms of achieving early improvement in high-risk patients with HAP (excluding
VAP) and in some subgroups of high-risk CAP patients.
Trial registration: NCT00210964: registered September 21, 2005; NCT00229008: registered September 29, 2005;
NCT00326287: registered May 16, 2006.
Keywords: Ceftobiprole, Cephalosporin, Community-acquired pneumonia, Hospital-acquired pneumoniaBackground
Pneumonia is a common bacterial infection, especially in
the elderly. The elderly population is increasing world-
wide [1] and consequently the clinical and economic
burden of pneumonia is expected to increase in the fu-
ture [2–4]. The severity and outcome of pneumonia is
dependent on a variety of external factors, such as the
causative pathogen and treatment approach [5].* Correspondence: Kamal.hamed@basilea.com
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(http://creativecommons.org/publicdomain/zePatient-related factors are also involved, with poorer
outcomes in patients who are elderly (aged ≥65 years),
immunocompromised, malnourished or with multiple
comorbidities [5–8]. Elderly or severely ill patients with
pneumonia often present with several of these factors,
and are therefore at particularly high risk of mortality
and morbidity [6, 9, 10].
The healthcare costs associated with pneumonia are
high and represent a large economic burden [3, 11–16].
Furthermore, the costs associated with pneumonia in-
crease substantially in elderly patients or those with a
chronic or immunocompromising disease, because of ale is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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management of underlying comorbidities [11, 13, 17].
Clearly, it is therefore important to ensure that first-line
treatment options for high-risk patients with pneumonia
are effective in both improving patient outcomes and
minimising the burden of pneumonia on the healthcare
system.
Ceftobiprole medocaril is an advanced-generation intra-
venous (i.v.) cephalosporin antibiotic. It is the first ceph-
alosporin approved in European countries for both
community-acquired pneumonia (CAP) and hospital
-acquired pneumonia (HAP) (excluding ventilator
-associated pneumonia [VAP]) [18]. Ceftobiprole, the ac-
tive moiety of ceftobiprole medocaril, has broad-spectrum
bactericidal activity against a wide range of Gram-positive
pathogens (including methicillin-resistant Staphylococcus
aureus [MRSA] and penicillin- and ceftriaxone-resistant
pneumococci) and Gram-negative pathogens (including
Enterobacteriaceae strains not producing extended
-spectrum β-lactamase and Pseudomonas aeruginosa)
[18–20].
The safety and efficacy of ceftobiprole have been dem-
onstrated in two large Phase III trials in patients with
CAP and HAP. The first study was a double-blind, mul-
ticentre, randomised study in 638 hospitalised patients
with CAP, which demonstrated that ceftobiprole was
non-inferior to ceftriaxone ± linezolid [21]. The second
study was a double-blind, multicentre, randomised study
in 781 patients with HAP, which demonstrated that cefto-
biprole treatment was non-inferior to a combined treat-
ment including ceftazidime plus linezolid, although non-
inferiority was not demonstrated in the subgroup of pa-
tients with VAP [22].
We performed a post hoc analysis of data from these
two Phase III studies [21, 22] to evaluate early improve-
ment outcomes in subgroups of high-risk patients
treated with ceftobiprole, compared with the respective
active-control therapies (ceftriaxone ± linezolid in CAP
and ceftazidime plus linezolid in HAP). The post hoc
analyses presented here include only patients with HAP,
excluding VAP, in accordance with the approved indica-
tion for ceftobiprole [18]. All mentions of HAP patients
hereafter exclude patients with VAP.
Methods
Study design
The study designs have previously been described in de-
tail elsewhere [21, 22]. Briefly, the CAP study [Clinical-
Trials.gov identifier NCT00326287] was a multicentre,
international, double-blind, non-inferiority study of hos-
pitalised adult patients with CAP undertaken in 103 cen-
tres between June 2006 and June 2007 [21]. Key
inclusion criteria comprised a diagnosis of acute bacter-
ial CAP requiring hospitalisation (with no hospitalisationduring the 14 days prior to onset of pneumonia symp-
toms) and treatment with i.v. antibiotics for at least
three days. Patients were also required to have at least
two of the following: cough; purulent sputum produc-
tion; rales or evidence of pulmonary consolidation; dys-
pnoea or tachypnoea; new onset hypoxaemia or
requirement for mechanical ventilation. Patients were
randomised in a 1:1 ratio to receive ceftobiprole, or cef-
triaxone ± linezolid; all treatments were given i.v. Ran-
domisation was stratified by Pneumonia Severity Index
(PSI) score (<91 or ≥91) and need for anti-
staphylococcal therapy at baseline. The primary end-
point was the clinical cure rate at the test-of-cure (TOC)
visit, defined as either resolution of signs and symptoms
of infection or sufficient improvement such that no fur-
ther antibacterial therapy was necessary, and improve-
ment or no adverse changes in findings on the chest
radiograph.
The HAP study [ClinicalTrials.gov identifiers:
NCT00210964, NCT00229008] was a multicentre, inter-
national, double-blind, non-inferiority study of adult pa-
tients with HAP undertaken at 157 centres between
April 2005 and May 2007 [22]. Key inclusion criteria
comprised: a clinical diagnosis of pneumonia after ≥72 h
stay in hospital or a chronic care facility; clinical signs
and symptoms of pneumonia; fever or leukocytosis/
leukopenia; new or persistent radiographic infiltrates;
and an Acute Physiology and Chronic Health Evaluation
II (APACHE II) score between 8 and 25. Patients were
randomised in a 1:1 ratio to receive ceftobiprole or
ceftazidime plus linezolid, with all treatments given
i.v. Randomisation was stratified by the presence of
VAP (defined as pneumonia developing >48 h after
onset of mechanical ventilation) and by APACHE II
score (8–19 or 20–25). The primary endpoint was
clinical cure at the TOC visit, defined as resolution of
signs and symptoms of infection, or improvement to
such an extent that no further antimicrobial therapy
was necessary, in the absence of systemic non-study
antibiotics.
Both studies were conducted in accordance with Inter-
national Conference on Harmonization Guidelines for
Good Clinical Practice, the Declaration of Helsinki, and
applicable local regulations. Each study protocol was ap-
proved by an Independent Ethics Committee, and all pa-
tients provided written informed consent before any
study procedures were carried out.
Post hoc analysis
Patient population
The selection of risk factors was based on published lit-
erature demonstrating poorer outcomes in certain
groups of pneumonia patients. For the CAP study, the
high-risk group comprised patients with any of the
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search Team (PORT) risk score ≥III [23, 24]; aged ≥75
years [3]; sepsis [3]; chronic obstructive pulmonary dis-
ease (COPD) [3]; bacteraemia [3]; or treated in an inten-
sive care unit (ICU) [25]. Patients from the HAP study
who were included in the high-risk group comprised
those with mechanical ventilation at any time during the
study (but not VAP patients) [5, 26] or with any of the
following at baseline: APACHE II score ≥15 [5, 27]; aged
≥75 years [28–30]; bacteraemia [5, 31]; treated in an ICU
[32]; COPD [33]; and >10 comorbidities documented in
the patient’s medical history [5, 34].
Study endpoints
Efficacy assessment of antimicrobial therapy has been
traditionally based on the clinical response rate at a
TOC visit after the treatment course (the primary end-
point in both of the CAP and HAP studies included
here). However, in recent years, additional response as-
sessments have emerged that may provide further clinic-
ally relevant insights into the efficacy of antimicrobial
therapy. Based on evidence gathered from historical and
modern studies of antibiotic therapy in CAP, the Foun-
dation for the National Institutes of Health (FNIH) ob-
served that antimicrobial treatment achieved symptom
improvement by Day 3 after the start of treatment in ap-
proximately three-quarters of cases [35]. Accordingly,
the FNIH recommended that symptom improvement at
approximately three days after the start of treatment
could be used as a relevant treatment response measure
[35]. Recent regulatory guidance from the US Food and
Drug Administration (FDA) endorsed early symptom
improvement (as measured on Day 3–5) as a primary
outcome measure in clinical trials investigating CAP
[36]. The FNIH Biomarkers Consortium has not yet de-
fined new endpoints for antimicrobial efficacy trials in
HAP, but noted recently that a clinical response end-
point based on symptoms up to study Day 7 may be
relevant [37].
Based on these recommendations, rate of early clinical
response was used as the primary efficacy outcome
measure in our analysis. Data collected at the first clin-
ical assessment following baseline were used to assess
early improvement (Day 3 in CAP and Day 4 in HAP).
Additional outcome measures in high-risk patient
groups were clinical cure at TOC and all-cause mortal-
ity, as well as safety and tolerability.
Study 1: Community-acquired pneumonia
Early clinical improvement was defined as clinical re-
sponse at Day 3 after randomisation, as proposed by the
FNIH [35]. Clinical response was defined as improve-
ment or resolution of two or more symptoms (cough,
pleuritic chest pain, dyspnoea and sputum production)and no worsening of other symptoms. The duration of
i.v. therapy and the proportion of patients who, after
three days, met the protocol-defined criteria for switch
to oral cefuroxime were calculated post hoc.
The intention-to-treat (ITT) population included all
randomised patients, excluding 28 randomised patients
enrolled at a single study site (14 in each treatment
arm), who were removed from the analysis due to sig-
nificant deviations from the study protocol. The clinic-
ally evaluable (CE) population included all treated
patients with a diagnosis of CAP, unless the duration of
study drug therapy was less than 48 h or less than 80%
of the intended dose, cure took place within <5 days, or
if other pre-specified exclusion criteria applied.
Analyses were conducted in the overall high-risk
group, as well in subgroups of patients with each of the
following individual risk factors: PORT risk score ≥III;
PORT risk score ≥IV; age ≥75 years; sepsis; COPD; bac-
teraemia; and treated in an ICU. Analyses were only per-
formed when the numbers of patients in both treatment
arms were 20 or above.
Study 2: Hospital-acquired pneumonia
Early clinical improvement was defined as clinical im-
provement at Day 4 after randomisation, based on grad-
ing ‘improved from baseline’, ‘unchanged from baseline’
or ‘worsened from baseline’ by the investigator. Patients
were analysed according to whether or not they achieved
a clinical response, defined as either clinical cure (as per
the primary endpoint) or improvement of at least two
symptoms according to an investigator assessment at
Day 4.
The ITT population included all randomised patients.
The CE population included patients who received at
least one dose of study medication and were clinically
evaluable at the TOC visit, excluding patients who re-
ceived systemic non-study antibiotics for indications
other than pneumonia.
Endpoints were assessed in the subgroup of patients
with any high-risk factor, including mechanical ventila-
tion at any time during the study (or ≤48 h prior to de-
velopment of pneumonia) and any of the following
occurring at baseline: APACHE II score ≥15; aged ≥75
years; bacteraemia; treated in an ICU; COPD; and >10
comorbidities. Further analyses were conducted in add-
itional subgroups of patients defined by presence of each
of these risk factors individually, but only when the
number of patients in both treatment arms was 20 or
above.
All post hoc analyses performed were exploratory.
Therefore, endpoints were analysed descriptively with
two-sided 95% confidence interval (CI) values for treat-
ment difference, using a normal approximation, rather
than with any formal statistical testing, and no p values
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lyses and the lack of any formal statistical testing, no
correction for multiple comparisons was applied. The
post hoc analysis was performed using SAS version 9.3.
Results
Results of the post hoc analysis are presented here for
the CE population; corresponding data relating to the
ITT population are provided in the Additional files 1, 2,
3, 4, 5, 6 and 7.
Patient characteristics
From the CAP study, 469 patients were included in the
CE population (all-patients group). Of these, 231 had been
treated with ceftobiprole and 238 with ceftriaxone ± linez-
olid. The high-risk group included 193 patients treated
with ceftobiprole and 205 patients treated with ceftriaxone
± linezolid. From the HAP study, 383 patients were in-
cluded in the CE population (all-patients group); 198 pa-
tients were treated with ceftobiprole and 185 with
ceftazidime plus linezolid. In total, 169 patients treated
with ceftobiprole and 138 treated with ceftazidime plus li-
nezolid were included in the high-risk group. The number
of patients with each high-risk factor is provided in
Table 1. As the number of CAP and HAP patients with
bacteraemia at baseline was <20 in both treatment arms,
further analyses were not carried out for this subgroup.
The baseline characteristics for the all-patients groups
(including both low- and high-risk patients) from both
studies are provided in Additional file 1 and were previ-
ously described separately in detail [21, 22]. The baseline
characteristics for the high-risk groups are provided in
Table 2. In the high-risk CAP group, a higher proportion
of patients had sepsis at baseline compared with the
all-patients group (63.7–65.9% vs 53.2–56.7%). As ex-
pected, the percentage of patients aged ≥65 years was
higher in the high-risk groups compared with theTable 1 Patients in high-risk subgroup categories (CE population)
CAP HA
Baseline risk factor Ceftobiprole Ceftriaxone ± linezolid Ba
Any risk factor 193 205 An
PORT≥ III 126 117 AP
PORT≥ IV 51 58 >1
Sepsis 123 135 M
Bacteraemiab 7 14 Ba
Age≥ 75 years 39 50 Ag
COPD 51 59 CO
ICU 25 26 IC
aMechanical ventilation at baseline or at any point during the study
bFurther analyses were not conducted in the bacteraemia group as the number of
APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired
disease, HAP hospital-acquired pneumonia, ICU intensive care unit, PORT Patient Ouall-patients groups (CAP 44.9–45.6% vs 27.7–30.7%;
HAP 62.3–62.7% vs 52.4–56.1%).
In both the CAP and HAP high-risk groups, baseline
characteristics were generally similar between patients in
the ceftobiprole vs comparator arms, with a few notable
differences (Table 2). Firstly, in the CAP high-risk group,
the proportion of patients receiving add-on therapy for
suspected MRSA was higher in the ceftriaxone ± linezo-
lid arm (linezolid 14.6%) compared with the ceftobiprole
arm (placebo 9.8%). Secondly, in the HAP high-risk
group, there was a higher proportion of male patients in
the ceftobiprole arm compared with the ceftazidime plus
linezolid arm (69.2% vs 58.0%). Similarly, baseline char-
acteristics were broadly similar for high-risk patients
whether they had CAP or HAP (Table 2). However, a
higher proportion of patients with HAP were aged ≥65
years (62.3–62.7% patients), compared with CAP pa-
tients (44.9–45.6% of patients). Additionally, the propor-
tion of HAP patients with a valid pathogen at baseline
was approximately double that observed in CAP patients
(59.2–64.5% vs 30.6–33.2%).
In the overall high-risk CAP group, the majority of pa-
tients had a clinical improvement assessment at Day 3.
Two patients (1.0%) in the ceftobiprole arm and three
patients (1.5%) in the ceftriaxone ± linezolid arm did not
have a Day 3 assessment. Of these five patients, three
discontinued the study for reasons including withdrawal
of informed consent (n = 1), study medication deemed
ineffective (n = 1), and protocol deviation (n = 1). In the
overall HAP high-risk group, all patients in the ceftobi-
prole arm had a Day 4 assessment. Seven patients (5.1%)
in the ceftazidime plus linezolid arm did not have a Day
4 assessment, of whom six discontinued the study for
reasons including adverse event (AE; n = 1), death (n =
3), clinical failure (n = 1) and discharge to a nursing
home (n = 1). Patient characteristics for the ITT popula-
tion are provided in Additional files 2–4.P (excluding VAP)
seline risk factor Ceftobiprole Ceftazidime plus linezolid
y risk factor 169 138
ACHE score≥ 15 67 59
0 comorbidities 63 61
echanical ventilationa 38 37
cteraemiab 15 11
e≥ 75 years 59 54
PD 55 39
U 73 59
patients in both treatment arms was below 20
pneumonia, CE clinically evaluable, COPD chronic obstructive pulmonary
tcome Research Team, VAP ventilator-associated pneumonia








Male 115 (59.6) 123 (60.0)
Age≥ 65 years 88 (45.6) 92 (44.9)
Sepsis 123 (63.7) 135 (65.9)
Pre-study antibiotics within 24 h 97 (50.3) 121 (59.0)
Valid pathogen at baseline 59 (30.6) 68 (33.2)
Patients with linezolid usea 19 (9.8) 30 (14.6)







Male 117 (69.2) 80 (58.0)
Age≥ 65 years 106 (62.7) 86 (62.3)
Sepsis 122 (72.2) 109 (79.0)
APACHE score≥ 15 67 (39.6) 59 (42.8)
Ventilation at baseline 22 (13.0) 24 (17.4)
Pre-study antibiotics within 24 h 101 (59.8) 81 (58.7)
Valid pathogen at baseline 100 (59.2) 89 (64.5)
Anti-pseudomonal antibioticsb 24 (14.2) 16 (11.6)
aCAP patients suspected of MRSA infection received add-on linezolid if randomised to ceftriaxone; if randomised to ceftobiprole, they received add-on placebo
instead of linezolid
bEmpirical treatment with antibiotic therapy was added to the study treatment for 48 h in patients with a suspected infection due to Pseudomonas aeruginosa or
for 5–7 days in patients with proven infection due to Pseudomonas aeruginosa
APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, HAP hospital-acquired pneumonia, MRSA
methicillin-resistant Staphylococcus aureus, VAP ventilator-associated pneumonia
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Early clinical improvement
In patients with CAP the between-treatment difference
in the proportion of patients with an early clinical im-
provement at Day 3 was <10%, in both the all-patients
and the overall high-risk patient groups (Fig. 1a). When
stratified by risk factor, between-treatment differences of
>10% were observed in high-risk CAP patients aged 75
years or older, in patients with COPD at baseline, in ICU
patients, and in patients with PORT risk score ≥4 (Fig. 1a).
Each of these differences favoured ceftobiprole over ceftri-
axone ± linezolid. Furthermore, in the subgroup of pa-
tients aged 75 years or older and in the subgroup of
patients with COPD at baseline, these treatment differ-
ences were associated with 95% CI that did not cross zero
(patients aged 75 years or older: treatment difference 16.3,
95% CI 1.8, 30.8; patients with COPD at baseline: treat-
ment difference 20.1, 95% CI 8.8, 31.1).
In patients with HAP, a treatment difference of >10%
in the percentage of patients with an early clinical im-
provement at Day 4 was observed in the overall
high-risk patient group (Fig. 1b). This treatment differ-
ence (12.5%) was associated with 95% CI that did notcross zero (95% CI 3.5, 21.4). When stratified by risk fac-
tor (Fig. 1b), a between-treatment difference of >10%
was observed in the subgroup of patients with >10 co-
morbidities at baseline. Again, this treatment difference
(15.3%) favoured ceftobiprole over the comparator (cef-
tazidime plus linezolid) and the 95% CI did not cross
zero (95% CI: 0.3, 30.4).
When stratified by causative pathogen, in the CAP
study, a between-treatment difference of >10% in the
proportion of high-risk patients with an early clinical
improvement at Day 3 was observed in patients with any
S. pneumoniae (Fig. 1c) (12.7%, favouring ceftobiprole;
95% CI − 6.4, 31.8). In the HAP study, between-
treatment differences of >10% in the proportion of
high-risk patients with early clinical improvement were
observed in patients with any Gram-positive pathogen
(14.8%), any Gram-negative pathogen (11.8%) or any S.
aureus (23.0%). All of these treatment differences
favoured ceftobiprole over ceftazidime plus linezolid.
Furthermore, for the S. aureus group, the 95% CIs did
not include zero (5.6, 40.5).
In the ITT population, no between-treatment differ-
ences of >10% were observed in the proportion of CAP
Fig. 1 Early improvement in CAP or HAP patients, by risk factors and causative pathogen. Top panel. Early improvement at Day 3 in patients with
CAP, by risk factor (CE population). Middle panel. Early improvement at Day 4 in patients with HAP (excluding VAP) by risk factor (CE population).
Lower panel. Early improvement in high-risk group patients by pathogen type (CE population). aThe comparator treatment was ceftriaxone ± linezolid
in CAP patients and ceftazidime plus linezolid in HAP (excluding VAP) patients. bBetween treatment difference calculated as ceftobiprole minus
comparator cTwo-sided 95% confidence interval is based on a normal approximation to the difference of the two proportions. Analyses were not
conducted in bacteraemia high-risk groups as the number of CAP and HAP patients in both treatment arms was <20. Early clinical improvement is
defined as improved or cured at Day 3 in patients with CAP, and improved or cured at Day 4 in patients with HAP (excluding VAP). Early clinical
improvements were evaluated by the investigator, based on an assessment of symptoms using standardised criteria
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the all-patients and high-risk groups. When stratified by
risk factor and causative pathogen, in the CAP study,
treatment differences of >10% in early response were ob-
served in the PORT ≥IV group (11.9% favouring ceftobi-
prole; 95% CI − 1.2, 25.0) and in patients with any
Gram-negative pathogen (− 11.4% favouring ceftriaxone
± linezolid; 95% CI − 26.0, 3.3) (Additional file 6). In the
HAP study, treatment differences of >10% were observedin patients with >10 comorbidities (11.9%, favouring cef-
tobiprole; 95% CI − 1.4, 24.9), in patients with any
MRSA (14.9%, favouring ceftobiprole; 95% CI − 9.1,
38.8) and in patients with any P. aeruginosa (14.8%,
favouring ceftobiprole; 95% CI − 9.2, 38.9).
Clinical cure at TOC visit
There were no treatment differences of >10% in the propor-
tion of CAP and HAP patients achieving a clinical cure at
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groups (Table 3). When analysed by causative pathogen and
risk factor, treatment differences of >10% in clinical cure at
TOC were observed in ICU patients in the CAP study
(10.5%, favouring ceftobiprole; 95% CI − 15.2, 36.1) and pa-
tients receiving mechanical ventilation in the HAP study
(14.7%, favouring ceftobiprole; 95% CI − 7.6, 37.1) (Table 3).
Similarly, in the ITT population, treatment differences in
the proportion of CAP and HAP patients achieving a clin-
ical cure at the TOC visit were mostly ≤10% (Add-
itional file 5). Exceptions, both in the HAP study, included
patients with mixed or polymicrobial infections (treatment
difference − 11.8%, favouring ceftazidime plus linezolid;
95% CI − 32.0, 8.3) and patients with COPD (treatment dif-
ference 10.6%, favouring ceftobiprole; 95% CI − 5.1, 26.4).
30-day all-cause mortality
Overall, no between-treatment differences of >10% were





All patients (CAP) 231/238 86.6/
High-risk patients (CAP) 193/205 86.0/
Any Gram-positive 29/40 89.7/
Any Gram-negative 34/33 82.4/
Any S. pneumoniae 26/33 92.3/
PORT ≥ III 126/117 86.5/
PORT ≥ IV 51/58 90.2/
Sepsis 123/135 84.6/
Age≥ 75 years 39/50 92.3/
COPD 51/59 86.3/
ICU 25/26 72.0/
All patients (HAP, excl. VAP) 198/185 77.8/
High-risk patients (HAP, excl. VAP) 169/138 75.7/
Any Gram-positive 52/53 69.2/
Any Gram-negative 65/60 67.7/
Mixed/polymicrobial 29/35 62.1/
Any S. aureus 35/38 68.6/
APACHE score≥ 15 67/59 68.7/
>10 comorbidities 63/61 73.0/
Mechanical ventilation 38/37 55.3/
Age≥ 75 years 59/54 72.9/
COPD 55/39 83.6/
ICU 73/59 69.9/
aBetween treatment difference calculated as ceftobiprole minus ceftriaxone ± linezo
patients with HAP (excluding VAP)
bTwo-sided 95% CI is based on a normal approximation to the difference of the tw
APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired
obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive car
Research Team, TOC test-of-cure, VAP, ventilator-associated pneumoniapatients, for both the all-patients and high-risk groups
(Fig. 2a; Fig. 2b). When stratified by risk factor, a
between-treatment difference of >10% in 30-day
all-cause mortality was observed in CAP patients treated
in the ICU (− 11.5%; favouring ceftriaxone ± linezolid;
95% CI − 23.8, 0.7) (Fig. 2a). No between-treatment dif-
ferences in all-cause mortality of >10% were observed in
high-risk HAP patients when analysed by risk factor
(Fig. 2b).
When analysed by causative pathogen, between-
treatment differences in mortality rate of >10% were ob-
served in high-risk HAP patients with any
Gram-positive pathogen (− 11.2%; favouring ceftazidime
plus linezolid; 95% CI − 23.1, 0.7) or with any S. aureus
(− 12.5%; favouring ceftazidime plus linezolid; 95%
CI − 28.4, 3.5) (Fig. 2c).
In the ITT population, there were no
between-treatment differences of >10% in 30-day
all-cause mortality for both CAP and HAP patients, inype (CE population)
al cure at TOC
eftobiprole/ comparator)
Treatment difference (%)a 95% CIb
87.4 −0.8 −6.9, 5.3
86.8 −0.8 −7.6, 5.9
90.0 −0.3 −14.8, 14.1
90.9 −8.6 −24.7, 7.6
90.9 1.4 −12.8, 15.6
86.3 0.2 −8.4, 8.8
84.5 5.7 −6.7, 18.1
86.7 −2.1 −10.7, 6.5
86.0 6.3 −6.4, 19.1
86.4 −0.2 −13.0, 12.7
61.5 10.5 −15.2, 36.1
76.2 1.6 −6.9, 10.0
71.7 4.0 −5.9, 13.9
69.8 −2.5 −19.9, 15.0
73.3 −5.6 −21.6, 10.3
68.6 −6.5 −29.9, 16.9
71.1 −2.5 − 23.6, 18.6
64.4 4.2 −12.3, 20.8
67.2 5.8 −10.3, 21.9
40.5 14.7 −7.6, 37.1
77.8 −4.9 −20.8, 11.0
76.9 6.7 −9.7, 23.2
66.1 3.8 −12.3, 19.8
lid for patients with CAP, and ceftobiprole minus ceftazidime plus linezolid for
o proportions
pneumonia, CE clinically evaluable, CI confidence interval, COPD chronic
e unit, MRSA methicillin-resistant Staphylococcus aureus, PORT Patient Outcome
Fig. 2 30-day all-cause mortality in CAP or HAP patients, by risk factors and causative pathogen. Top panel. 30-day all-cause mortality in patients with
CAP, by risk factor (CE population). Middle panel. 30-day all-cause mortality in patients with HAP (excluding VAP) by risk factor (CE population). Lower
panel. 30-day all-cause mortality in high-risk group patients by pathogen type (CE population). aThe comparator treatment was ceftriaxone ± linezolid
in CAP patients and ceftazidime plus linezolid in HAP (excluding VAP) patients. bBetween treatment difference calculated as ceftobiprole minus
comparator. cTwo-sided 95% confidence interval is based on a normal approximation to the difference of the two proportions
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by risk factor, a between-treatment difference of >10%
in 30-day all-cause mortality was observed in patients
with bacteraemia in the HAP study (− 16.2%, favour-
ing ceftazidime plus linezolid; 95% CI − 40.6, 8.2).
When stratified by causative pathogen, a
between-treatment difference of >10% in 30-day
all-cause mortality was observed in patients with any
Gram-positive pathogen in the HAP study (− 11.5%,
favouring ceftazidime plus linezolid; 95% CI − 24.2, 1.3)
(Additional file 7).Safety
Safety findings in the all-patients groups from both stud-
ies have previously been reported and discussed in detail
[21, 22]. In the high-risk populations included here, the
incidence of treatment-emergent AEs was broadly simi-
lar in CAP and HAP patients (Table 4). A higher propor-
tion of patients with HAP reported serious AEs (SAEs)
compared with CAP patients, in both the all-patients
and high-risk groups (Table 4).
The proportions of ceftobiprole-treated CAP patients
experiencing AEs, SAEs, treatment-related AEs,

























AE 163 (70.6) 149 (62.6) 141 (71.2) 140 (75.7) 138 (71.5) 133 (64.9) 126 (74.6) 112 (81.2)
SAE 23 (10.0) 24 (10.1) 53 (26.8) 39 (21.1) 21 (10.9) 22 (10.7) 51 (30.2) 33 (23.9)
Treatment-related AE 82 (35.5) 61 (25.6) 51 (25.8) 49 (26.5) 70 (36.3) 57 (27.8) 46 (27.2) 43 (31.2)
Treatment-related SAE 2 (0.9) 3 (1.3) 7 (3.5) 3 (1.6) 2 (1.0) 2 (1.0) 7 (4.1) 3 (2.2)
SAE leading to death 3 (1.3) 6 (2.5) 27 (13.6) 28 (15.1) 3 (1.6) 6 (2.9) 26 (15.4) 25 (18.1)
AE adverse event, CAP community-acquired pneumonia, CE clinically evaluable, HAP hospital-acquired pneumonia, SAE serious adverse event, VAP
ventilator-associated pneumonia
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similar in the all-patients and high-risk groups (Table 4).
In the ceftobiprole arm, AEs were reported by 71.5% of
high-risk patients vs 70.6% of all patients, with SAEs re-
ported by 10.9 and 10.0% of all patients and high-risk
patients, respectively. Treatment-related AEs and SAEs
were reported by 36.3% of high-risk patients vs 35.5% of
all patients and 1.0% of high-risk patients vs 0.9% of all
patients, respectively. AEs leading to death occurred in
1.6% of high-risk patients vs 1.3% of all patients.
In the ceftobiprole arm, the proportion of high-risk
HAP patients reporting AEs, SAEs, treatment-related
AEs, treatment-related SAEs and AEs leading to death
was comparable with the all-patients group (Table 4).
AEs were reported by 74.6% of high-risk patients vs
71.2% of all patients. A comparable proportion of HAP
patients in the high-risk group and all-patients group re-
ported SAEs (30.2% vs 26.8%), related AEs (27.8% vs
25.8%), and SAEs leading to death (15.4% vs 13.6%).
The safety profiles of ceftobiprole and the comparator
treatments were broadly similar, with some minor differ-
ences (Table 4). In high-risk CAP patients, a higher pro-
portion of patients receiving ceftobiprole reported
treatment-emergent AEs, compared with patients receiving
ceftriaxone ± linezolid (71.5% vs 64.9%). However, in
high-risk HAP patients, a higher proportion of pa-
tients receiving ceftazidime plus linezolid reported
treatment-emergent AEs compared with patients re-
ceiving ceftobiprole (81.2% vs 74.6%). In high-risk
HAP patients, the incidence of treatment-emergent
SAEs was higher in patients receiving ceftobiprole
compared with patients receiving ceftazidime plus li-
nezolid (30.2% vs 23.9%). In high-risk CAP patients,
the incidence of treatment-emergent SAEs was com-
parable between the treatment groups (10.9% vs
10.7%).
Discussion
The results of this exploratory post hoc analysis of two
large randomised controlled trials indicate thatceftobiprole treatment is effective in severely ill patients
with pneumonia at risk of poor outcomes. In high-risk
patients with CAP or HAP, ceftobiprole treatment dem-
onstrated similar results to the comparator treatment
(ceftriaxone ± linezolid in CAP and ceftazidime plus li-
nezolid in HAP patients) in terms of early clinical im-
provement, clinical cure at TOC, and all-cause
mortality. Furthermore, in high-risk patients with HAP,
a higher percentage of patients had early clinical im-
provement in the ceftobiprole group compared with cef-
tazidime plus linezolid treatment (between-treatment
difference: 12.5% [95% CI: 3.5, 21.4]).
Potential for improved clinical outcomes with ceftobi-
prole compared with the active-control therapies was
observed in several high-risk patient subgroups. A
higher proportion of ceftobiprole-treated CAP patients
aged ≥75 years or with COPD at baseline, and HAP pa-
tients with >10 baseline comorbidities had early clinical
response compared with patients who received the
active-control therapy. Overall, these findings suggest
that the rapid bactericidal action of ceftobiprole [38]
may have advantages over other cephalosporins in
high-risk patients with HAP (excluding VAP) and in
some subgroups of high-risk patients with CAP, in
whom rapid improvement is urgently required to ensure
better outcomes.
These results are timely, given that recent guidance
documents produced by the FNIH and the FDA have
recommended early symptom improvement (FNIH: 3
days after the start of treatment; FDA: 3–5 days) may be
a useful measure of treatment response in CAP [35, 36].
Such measures may also be useful in HAP, as the FNIH
Biomarkers Consortium has noted recently that defini-
tions of response based on symptoms up to study Day 7
may be relevant [37]. However, a firm consensus on this
point has not yet been reached.
These findings build on the results reported in the ori-
ginal publications. Notably, the early improvement ob-
served in high-risk HAP patients was also observed in
the full population; in the CE population, a higher
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tobiprole group showed early improvement at Day 4
compared with the ceftazidime/linezolid group (86.9% vs
78.4%; treatment difference 8.5 [95% CI: 0.9, 16.1]) [22].
In both trials, ceftobiprole was generally as effective as
the comparator across risk groups in terms of clinical
cure at TOC [21, 22].
Few differences in clinical outcomes were observed be-
tween treatments when analysed by causative pathogen
type, with the exception of high-risk HAP patients with any
S. aureus pathogen. In this subgroup, a higher proportion
of patients treated with ceftobiprole had early improvement
at Day 4 compared with the comparator treatment.
The results of this post hoc analysis confirm the initial
safety results from these Phase III trials, which demon-
strated that ceftobiprole treatment for CAP and HAP is
well-tolerated, with a safety profile that is consistent
with other cephalosporins [21, 22]. The incidence of AEs
in the CAP and HAP high-risk group was similar to that
observed in the all-patients group, suggesting that the
safety profile of ceftobiprole treatment is not altered in
high-risk CAP and HAP patients.
Baseline characteristics were similar in high-risk CAP and
HAP patients included in this post hoc analysis. This simi-
larity demonstrates that no significant differences exist be-
tween high-risk HAP and CAP patients in terms of
underlying characteristics and risk factors, and that the
population studied can be considered as fairly homogenous.
Several limitations of this exploratory post hoc analysis
need to be taken into consideration when interpreting
the results. Notably, the sample size was relatively small,
especially in some of the subgroup analyses of individual
risk factors. In addition, no formal hypothesis testing
was planned or undertaken, and no correction was made
for the multiple comparisons performed, which, together
with the small sample size, increased the risk of chance
findings. Furthermore, the original studies were not
powered to detect statistical treatment differences be-
tween subgroups of patients. The results of the post hoc
analysis therefore need to be interpreted with caution.
Another limitation to be considered is that the original
studies of ceftobiprole in CAP and HAP patients in-
cluded a highly controlled patient population, in order
to allow a comparison of ceftobiprole with the reference
treatment. Although the population included in the
HAP study was noted to be representative of nosocomial
pneumonia patients in terms of age, underlying condi-
tions and severity of disease, the patients included in this
post hoc analysis may not be fully representative of a
‘real-life’ population [22].
Conclusions
Ceftobiprole appears to be an efficacious and generally
well-tolerated therapy for patients with pneumonia whoare severely ill or at high risk of poor outcomes. The re-
sults of this study, which analysed the clinically evaluable
population, provide preliminary evidence that ceftobi-
prole may be associated with early improvement in these
patient groups. Particularly notable results seeming to
favour ceftobiprole over comparators were observed in
high-risk patients with HAP (excluding VAP) and in
some subgroups of high-risk patients with CAP, such as
those aged ≥75 years or with COPD. Given the explora-
tory nature of these analyses, the results should be inter-
preted with caution.Additional files
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